<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
- -------------------------------------------------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) May 20, 1996
Chiron Corporation
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-12798 94-2754624
- -------------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
4560 Horton Street, Emeryville, CA 94608
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (510) 655-8730
N/A
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
1
<PAGE>
ITEM 5. OTHER EVENTS.
On May 20, 1996, Chiron Corporation issued a press release, the text of
which is attached hereto as Exhibit 99.1, announcing that its Board of Directors
has declared a 4-for-1 stock split effected in the form of a dividend on the
company's common stock distributed on or about August 2, 1996, to stockholders
of record on July 19, 1996.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
Sequentially Numbered
Exhibit Number Page
-------------- ---------------------
99.1 Press Release dated
May 20, 1996
referred to in Item 5 above
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CHIRON CORPORATION
Date: May 21, 1996 By: /s/ William G. Green
-------------------------------------
William G. Green
Senior Vice President and
General Counsel
3
<PAGE>
INDEX TO EXHIBITS
Sequentially
Exhibit No. Description Numbered Page
- ----------- ----------- -------------
99.1 Press Release dated May 20, 1996.
4
<PAGE>
EXHIBIT 99.1
RELEASE DATE: Immediate
CONTACT: Larry Kurtz
Vice President, Corporate Communications
(510) 601-2476
CHIRON DECLARES 4-FOR-1 STOCK SPLIT
EMERYVILLE, CALIF., MAY 20, 1996 -- Chiron Corporation (NASDAQ:CHIR) announced
today that its Board of Directors has declared a 4-for-1 stock split effected in
the form of a dividend on the company's common stock distributed on or about
August 2, 1996, to stockholders of record on July 19, 1996. Stockholders will
receive three additional shares of Chiron common stock for each share of common
stock owned on the record date. No action is required by stockholders; Chiron's
transfer agent, Continental Stock Transfer and Trust Company of New York City,
will distribute the additional shares to holders of record, and stockholders
whose shares are held in street name will have their accounts credited for the
additional shares.
Issuance of the new shares will increase the number of currently
outstanding Chiron common shares to approximately 169 million shares. All
warrants, stock options and convertible bond conversion rates will be adjusted
for the effect of the split. At the Chiron Annual Meeting of Stockholders held
May 16, 1996, stockholders voted to increase the number of shares that the
company is authorized to issue from 100 million to 500 million. Chiron, founded
in May 1981, became a public company in 1983 at a price of $12 per share and has
not previously split its stock since it became a public company.
Chiron Corporation is a science-driven healthcare company that combines
diagnostic, vaccine and therapeutic strategies for controlling disease.
Headquartered in Emeryville, California, with operations on four continents,
Chiron had revenues in 1995 of $1.1 billion. Chiron participates in four global
healthcare markets: diagnostics, including immunodiagnostics, critical care
diagnostics and new quantitative probe tests; therapeutics, with an emphasis on
oncology and infectious disease; pediatric and adult vaccines; and ophthalmic
surgical products for the correction of vision. Chiron also has research
programs in gene therapy, combinatorial chemistry, cancer, infectious and
cardiovascular disease, and critical care.
# # #
